• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bioventus Inc. - Class A Common Stock (NQ:BVS)

    9.920 -0.040 (-0.40%)
    Streaming Delayed Price Updated: 9:50 AM EDT, Apr 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 25,127
    Open 9.910
    Bid (Size) 9.900 (300)
    Ask (Size) 9.940 (200)
    Prev. Close 9.960
    Today's Range 9.800 - 9.930
    52wk Range 5.810 - 10.76
    Shares Outstanding 10
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
    Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
    Via Chartmill

    Performance

    YTD
    +37.6%
    +37.6%
    1 Month
    +10.7%
    +10.7%
    3 Month
    +25.3%
    +25.3%
    6 Month
    +42.9%
    +42.9%
    1 Year
    +33.5%
    +33.5%

    More News

    Read More
    News headline image
    Bioventus (BVS) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings World Trade
    Bioventus Inc (NASDAQ:BVS) Reports Q4 Earnings Beat and Strong 2026 Outlook ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 6, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For May 6, 2025 ↗
    Via Benzinga
    News headline image
    Examining the Future: Bioventus's Earnings Outlook ↗
    Via Benzinga
    News headline image
    Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Bioventus Inc (NASDAQ:BVS) Reports Q3 2025 Earnings Beat and Strong Profitability Growth ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Bioventus Reports Third Quarter Financial Results
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus Inc. (NASDAQ:BVS) Reports Mixed Q2 2025 Earnings Amid Muted Market Reaction ↗
    Via Chartmill
    News headline image
    Bioventus Reports Second Quarter Financial Results
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
    From Bioventus, Inc.
    Via GlobeNewswire
    News headline image
    Bioventus Reports First Quarter Financial Results
    From Bioventus, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Bioventus Inc. - Class A Common Stock publicly traded?
    Yes, Bioventus Inc. - Class A Common Stock is publicly traded.
    What exchange does Bioventus Inc. - Class A Common Stock trade on?
    Bioventus Inc. - Class A Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Bioventus Inc. - Class A Common Stock?
    The ticker symbol for Bioventus Inc. - Class A Common Stock is BVS on the Nasdaq Stock Market
    What is the current price of Bioventus Inc. - Class A Common Stock?
    The current price of Bioventus Inc. - Class A Common Stock is 9.920
    When was Bioventus Inc. - Class A Common Stock last traded?
    The last trade of Bioventus Inc. - Class A Common Stock was at 04/29/26 09:50 AM ET
    What is the market capitalization of Bioventus Inc. - Class A Common Stock?
    The market capitalization of Bioventus Inc. - Class A Common Stock is 99.20
    How many shares of Bioventus Inc. - Class A Common Stock are outstanding?
    Bioventus Inc. - Class A Common Stock has 99 shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.